Close Menu
Skip to main content
GenomeWeb
360Dx
Precision Oncology News
Precision Oncology News
*
*
Show password
Forgot your password?
Subscribe
Contains all of these words:
You may find more results for this query on our sister sites:
GenomeWeb
and
360Dx
.
Business & Policy
Business News
Regulatory News
Reimbursement
Biomarkers
BRCA
EGFR
HER2
KRAS
BRAF
ROS1
ALK
PD-L1
Cancer Specialties
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Brain Cancer
Melanoma
Pediatric Cancer
Oncology Trends
Next-Generation Sequencing
Minimal Residual Disease
Microsatellite Instability Testing
Immunotherapy
Liquid Biopsy
Resources
Webinars
White Papers
Conferences & Events
Partner Content
Menu
Home
›
About Us
›
Our Staff
›
Allan Nixon
Allan Nixon
Director of Business Development, Premium Content
Phone Number
+1-212-651-5623
Email
[email protected]
Breaking
News
Blueprint Medicine's Ayvakyt Garners Conditional European Commission Authorization in GIST
BMS's Opdivo Prolongs Disease-Free Survival as Adjuvant Treatment for Patients With Bladder Cancer
Blueprint Medicines to Pursue Ayvakit Approval in Cancer-Causing Mast Cell Disorder
Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay
Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib
Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD
Sign Up for Topical Newsletters
